<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00484419</url>
  </required_header>
  <id_info>
    <org_study_id>Wel-409</org_study_id>
    <nct_id>NCT00484419</nct_id>
  </id_info>
  <brief_title>Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin</brief_title>
  <official_title>Effects of Colesevelam HCl, AvandiaÂ® (Rosiglitazone Maleate), or JanuviaTM (Sitagliptin) on Glycemic Parameters and Lipid Profiles in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      A 16 week open-label study with subjects receiving background metformin monotherapy. 150
      subjects randomized 1:1:1 to receive 1 of the following: open-label colesevelam HCl, open
      label rosiglitazone, or open-label sitagliptin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 16 Endpoint</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>Change in HbA1c from Week 0(baseline) to Week 16 endpoint mean with standard deviation change = week 16 - week 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Change in Glycosylated Hemoglobin (HbA1c) From Week 0(Baseline) to Week 16 Endpoint Least Squares Mean</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>Change in HbA1c from Week 0(baseline)to Week 16 endpoint least squares mean with 95% confidence intervals, change = week 16 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 8</measure>
    <time_frame>8 weeks change = week 8- week 0.</time_frame>
    <description>change in HbA1c from Week 0(baseline) to week 8 mean and standard deviation change = week 8 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) From Week 0(Baseline) to Week 8 Least Squares Mean</measure>
    <time_frame>8 weeks change = week 8- week 0.</time_frame>
    <description>change in FPG from Week 0(baseline) to week 8 least squares mean and 95% confidence interval change = week 8 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG From Week 0(Baseline) to Week 16 Least Squares Mean</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>change in FPG from Week 0(baseline) to week 16 least squares mean and 95% confidence interval change = week 16 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in FPG From Week 0(Baseline) to Week 8</measure>
    <time_frame>8 weeks change = week 8- week 0.</time_frame>
    <description>mean change in FPG from Week 0(baseline) to Week 8 with standard deviation change = week 8 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in FPG From Week 0(Baseline) to Week 16</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>change in FPG from Week 0(baseline) to week 16 mean and standard deviation change = week 16 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin From Week 0(Baseline) to Week 8 Least Squares Mean</measure>
    <time_frame>8 weeks change = week 8- week 0.</time_frame>
    <description>change in fasting insulin from Week 0(baseline) to week 8 least squares mean and 95% confidence interval change = week 8 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin From Week 0(Baseline) to Week 16 Least Squares Mean</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>change in fasting insulin from Week 0(baseline) to week 16 least squares mean and 95% confidence interval change = week 16 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Fasting Insulin From Week 0(Baseline) to Week 8</measure>
    <time_frame>8 weeks change = week 8- week 0.</time_frame>
    <description>mean change in fasting insulin from Week 0(baseline) to week 8 with standard deviation change = week 8 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Fasting Insulin From Week 0(Baseline) to Week 16</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>mean change in fasting insulin from Week 0(baseline) to week 16 with standard deviation change = week 16 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Post-prandial Glucose From Week 0(Baseline) to Week 16 Least Squares Mean</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>change in post-prandial glucose from Week 0(baseline) to week 16 least squares mean with 95% confidence intervals change = week 16 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Post-prandial Glucose From Week 0(Baseline) to Week 16</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>mean change in post-prandial glucose from Week 0(baseline) to week 16 with standard deviation change = week 16 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Post-prandial Insulin From Week 0(Baseline) to Week 16</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>mean change in post-prandial insulin from Week 0(baseline) to week 16 with standard deviation change = week 16 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low-Density Lipoprotein-C(LDL-C) From Week 0(Baseline) to Week 16 Least Squares Mean</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>change in LDL-C from Week 0(baseline) to week 16 least squares mean with 95% confidence intervals change = week 16 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in LDL-C From Week 0(Baseline) to Week 16</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>mean change in LDL-C from Week 0(baseline) to week 16 with standard deviation change = week 16 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Change in LDL-C Levels From Week 0(Baseline) to Week 16</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>mean percent change in LDL-C levels from Week 0(baseline) to Week 16 mean with standard deviation change = week 16 - week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Change in LDL-C Levels From Week 0(Baseline) to Week 16 (Least Squares Mean)</measure>
    <time_frame>16 weeks change = week 16 - week 0.</time_frame>
    <description>percent change in LDL-C levels from Week 0(baseline) to Week 16 (least squares mean with 95% confidence interval)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>colesevelam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>colesevelam tablets 625 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosiglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rosiglitazone maleate 4mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sitagliptin phosphate tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam HCl</intervention_name>
    <description>coleveselam tablets 625 mg; 6 tablets/day</description>
    <arm_group_label>colesevelam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone maleate</intervention_name>
    <description>rosiglitazone tablets 4mg</description>
    <arm_group_label>rosiglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin phosphate</intervention_name>
    <description>sitagliptin phosphate tablets 100mg/day</description>
    <arm_group_label>sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HbA1C 7.0 % to 10.0% on metformin monotherapy; may be withdrawn from other
             (non-metformin) drugs if HbA1C is 6.5% to 9.5 % at screening.

        Exclusion Criteria:

          -  Subjects currently treated with a thiazolidinedione are excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiefland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gary</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>W. Bloomfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yonkers</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munroe Falls</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaneville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jersey Shore</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clemson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harriman</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2007</study_first_submitted>
  <study_first_submitted_qc>June 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2007</study_first_posted>
  <results_first_submitted>April 29, 2009</results_first_submitted>
  <results_first_submitted_qc>April 29, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2009</results_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colesevelam HCl,</keyword>
  <keyword>rosiglitazone</keyword>
  <keyword>sitagliptin</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 18 May 2007 to 14 December 2007 at 6 sites in Colombia, 7 sites in Mexico, and 20 sites in the United States of America.</recruitment_details>
      <pre_assignment_details>Subjects on metformin-combination therapy entered a 4-week washout period from non-metformin antidiabetic drug. Population is type 2 diabetes mellitus subjects on stable metformin regimen, who discontinued other antidiabetic drugs, glycemia not controlled, and low-density lipoprotein-C (LDL-C) &gt;=60 mg/dL and triglycerides &lt;500 mg/dL</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Colesevelam</title>
          <description>colesevelam tablets 625 mg</description>
        </group>
        <group group_id="P2">
          <title>Rosiglitazone</title>
          <description>rosiglitazone maleate 4mg</description>
        </group>
        <group group_id="P3">
          <title>Sitagliptin</title>
          <description>sitagliptin phosphate tablets 100mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>subject met discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>required restricted medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>subject unable to receive medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>subject relocated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>sponsor decision, randomized in error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Colesevelam</title>
          <description>colesevelam tablets 625 mg</description>
        </group>
        <group group_id="B2">
          <title>Rosiglitazone</title>
          <description>rosiglitazone maleate 4mg</description>
        </group>
        <group group_id="B3">
          <title>Sitagliptin</title>
          <description>sitagliptin phosphate tablets 100mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="56"/>
            <count group_id="B4" value="169"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" spread="9.19"/>
                    <measurement group_id="B2" value="54.7" spread="10.92"/>
                    <measurement group_id="B3" value="54.8" spread="9.76"/>
                    <measurement group_id="B4" value="55.4" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Insulin</title>
          <description>baseline fasting insulin</description>
          <units>uIU/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.406" lower_limit="1.63" upper_limit="47.77"/>
                    <measurement group_id="B2" value="9.945" lower_limit="1.22" upper_limit="42.37"/>
                    <measurement group_id="B3" value="8.886" lower_limit="1.32" upper_limit="24.02"/>
                    <measurement group_id="B4" value="9.396" lower_limit="1.22" upper_limit="47.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <description>baseline Fasting Plasma Glucose (FPG)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174.5" lower_limit="109" upper_limit="270"/>
                    <measurement group_id="B2" value="177.7" lower_limit="101" upper_limit="469"/>
                    <measurement group_id="B3" value="180.6" lower_limit="85" upper_limit="456"/>
                    <measurement group_id="B4" value="177.6" lower_limit="85" upper_limit="469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <description>baseline glycosylated hemoglobin</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.10" lower_limit="6.8" upper_limit="9.7"/>
                    <measurement group_id="B2" value="8.06" lower_limit="6.7" upper_limit="9.7"/>
                    <measurement group_id="B3" value="8.17" lower_limit="6.5" upper_limit="9.9"/>
                    <measurement group_id="B4" value="8.11" lower_limit="6.5" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage of Change in Glycosylated Hemoglobin (HbA1c) From Week 0(Baseline) to Week 16 Endpoint Least Squares Mean</title>
        <description>Change in HbA1c from Week 0(baseline)to Week 16 endpoint least squares mean with 95% confidence intervals, change = week 16 - week 0.</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Change in Glycosylated Hemoglobin (HbA1c) From Week 0(Baseline) to Week 16 Endpoint Least Squares Mean</title>
          <description>Change in HbA1c from Week 0(baseline)to Week 16 endpoint least squares mean with 95% confidence intervals, change = week 16 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>% change in HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" lower_limit="-0.52" upper_limit="-0.02"/>
                    <measurement group_id="O2" value="-0.58" lower_limit="-0.83" upper_limit="-0.32"/>
                    <measurement group_id="O3" value="-0.38" lower_limit="-0.64" upper_limit="-0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 8</title>
        <description>change in HbA1c from Week 0(baseline) to week 8 mean and standard deviation change = week 8 - week 0.</description>
        <time_frame>8 weeks change = week 8- week 0.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 8</title>
          <description>change in HbA1c from Week 0(baseline) to week 8 mean and standard deviation change = week 8 - week 0.</description>
          <units>% change in HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.772"/>
                    <measurement group_id="O2" value="-0.19" spread="0.842"/>
                    <measurement group_id="O3" value="-0.48" spread="0.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>For a treatment group, assuming a within-subject standard deviation of at most 1.15, a 2-sided t-test of the null hypothesis that the change from baseline (CFB) is zero will have 67% to 85% power to detect a difference of 0.4 to 0.5 with a sample size of 50 randomized subjects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0061</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For a treatment group, assuming a within-subject standard deviation of at most 1.15, a 2-sided t-test of the null hypothesis that the change from baseline (CFB) is zero will have 67% to 85% power to detect a difference of 0.4 to 0.5 with a sample size of 50 randomized subjects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1090</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For a treatment group, assuming a within-subject standard deviation of at most 1.15, a 2-sided t-test of the null hypothesis that the change from baseline (CFB) is zero will have 67% to 85% power to detect a difference of 0.4 to 0.5 with a sample size of 50 randomized subjects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 16 Endpoint</title>
        <description>Change in HbA1c from Week 0(baseline) to Week 16 endpoint mean with standard deviation change = week 16 - week 0.</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 16 Endpoint</title>
          <description>Change in HbA1c from Week 0(baseline) to Week 16 endpoint mean with standard deviation change = week 16 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>% change HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.898"/>
                    <measurement group_id="O2" value="-0.65" spread="0.836"/>
                    <measurement group_id="O3" value="-0.56" spread="1.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>For a treatment group, assuming a within-subject standard deviation of at most 1.15, a 2-sided t-test of the null hypothesis that the change from baseline (CFB) is zero will have 67% to 85% power to detect a difference of 0.4 to 0.5 with a sample size of 50 randomized subjects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0234</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For a treatment group, assuming a within-subject standard deviation of at most 1.15, a 2-sided t-test of the null hypothesis that the change from baseline (CFB) is zero will have 67% to 85% power to detect a difference of 0.4 to 0.5 with a sample size of 50 randomized subjects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For a treatment group, assuming a within-subject standard deviation of at most 1.15, a 2-sided t-test of the null hypothesis that the change from baseline (CFB) is zero will have 67% to 85% power to detect a difference of 0.4 to 0.5 with a sample size of 50 randomized subjects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG) From Week 0(Baseline) to Week 8 Least Squares Mean</title>
        <description>change in FPG from Week 0(baseline) to week 8 least squares mean and 95% confidence interval change = week 8 - week 0.</description>
        <time_frame>8 weeks change = week 8- week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG) From Week 0(Baseline) to Week 8 Least Squares Mean</title>
          <description>change in FPG from Week 0(baseline) to week 8 least squares mean and 95% confidence interval change = week 8 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6" lower_limit="-25.8" upper_limit="-5.3"/>
                    <measurement group_id="O2" value="-28.9" lower_limit="-38.9" upper_limit="-18.8"/>
                    <measurement group_id="O3" value="-17.4" lower_limit="-28.0" upper_limit="-6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FPG From Week 0(Baseline) to Week 16 Least Squares Mean</title>
        <description>change in FPG from Week 0(baseline) to week 16 least squares mean and 95% confidence interval change = week 16 - week 0.</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FPG From Week 0(Baseline) to Week 16 Least Squares Mean</title>
          <description>change in FPG from Week 0(baseline) to week 16 least squares mean and 95% confidence interval change = week 16 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3" lower_limit="-28.9" upper_limit="-5.7"/>
                    <measurement group_id="O2" value="-31.4" lower_limit="-42.5" upper_limit="-20.4"/>
                    <measurement group_id="O3" value="-24.4" lower_limit="-36.1" upper_limit="-12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in FPG From Week 0(Baseline) to Week 8</title>
        <description>mean change in FPG from Week 0(baseline) to Week 8 with standard deviation change = week 8 - week 0.</description>
        <time_frame>8 weeks change = week 8- week 0.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in FPG From Week 0(Baseline) to Week 8</title>
          <description>mean change in FPG from Week 0(baseline) to Week 8 with standard deviation change = week 8 - week 0.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="32.22"/>
                    <measurement group_id="O2" value="-30.8" spread="59.67"/>
                    <measurement group_id="O3" value="-18.6" spread="63.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0077</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0483</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in FPG From Week 0(Baseline) to Week 16</title>
        <description>change in FPG from Week 0(baseline) to week 16 mean and standard deviation change = week 16 - week 0.</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in FPG From Week 0(Baseline) to Week 16</title>
          <description>change in FPG from Week 0(baseline) to week 16 mean and standard deviation change = week 16 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" spread="41.53"/>
                    <measurement group_id="O2" value="-34.0" spread="63.55"/>
                    <measurement group_id="O3" value="-23.1" spread="59.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0133</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0125</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Insulin From Week 0(Baseline) to Week 8 Least Squares Mean</title>
        <description>change in fasting insulin from Week 0(baseline) to week 8 least squares mean and 95% confidence interval change = week 8 - week 0.</description>
        <time_frame>8 weeks change = week 8- week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin From Week 0(Baseline) to Week 8 Least Squares Mean</title>
          <description>change in fasting insulin from Week 0(baseline) to week 8 least squares mean and 95% confidence interval change = week 8 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>uIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.075" lower_limit="-3.442" upper_limit="3.592"/>
                    <measurement group_id="O2" value="-2.156" lower_limit="-5.720" upper_limit="1.408"/>
                    <measurement group_id="O3" value="4.002" lower_limit="0.371" upper_limit="7.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Insulin From Week 0(Baseline) to Week 16 Least Squares Mean</title>
        <description>change in fasting insulin from Week 0(baseline) to week 16 least squares mean and 95% confidence interval change = week 16 - week 0.</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin From Week 0(Baseline) to Week 16 Least Squares Mean</title>
          <description>change in fasting insulin from Week 0(baseline) to week 16 least squares mean and 95% confidence interval change = week 16 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>uIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.320" lower_limit="-1.757" upper_limit="1.116"/>
                    <measurement group_id="O2" value="-1.482" lower_limit="-2.922" upper_limit="-0.041"/>
                    <measurement group_id="O3" value="0.092" lower_limit="-1.363" upper_limit="1.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Fasting Insulin From Week 0(Baseline) to Week 8</title>
        <description>mean change in fasting insulin from Week 0(baseline) to week 8 with standard deviation change = week 8 - week 0.</description>
        <time_frame>8 weeks change = week 8- week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Fasting Insulin From Week 0(Baseline) to Week 8</title>
          <description>mean change in fasting insulin from Week 0(baseline) to week 8 with standard deviation change = week 8 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>uIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.107" spread="4.1543"/>
                    <measurement group_id="O2" value="-2.213" spread="6.5833"/>
                    <measurement group_id="O3" value="4.028" spread="20.1202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8596</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0257</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1862</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Fasting Insulin From Week 0(Baseline) to Week 16</title>
        <description>mean change in fasting insulin from Week 0(baseline) to week 16 with standard deviation change = week 16 - week 0.</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Fasting Insulin From Week 0(Baseline) to Week 16</title>
          <description>mean change in fasting insulin from Week 0(baseline) to week 16 with standard deviation change = week 16 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>uIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.212" spread="3.7914"/>
                    <measurement group_id="O2" value="-1.910" spread="8.5117"/>
                    <measurement group_id="O3" value="-0.419" spread="3.6669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7094</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1394</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4528</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Post-prandial Glucose From Week 0(Baseline) to Week 16 Least Squares Mean</title>
        <description>change in post-prandial glucose from Week 0(baseline) to week 16 least squares mean with 95% confidence intervals change = week 16 - week 0.</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Post-prandial Glucose From Week 0(Baseline) to Week 16 Least Squares Mean</title>
          <description>change in post-prandial glucose from Week 0(baseline) to week 16 least squares mean with 95% confidence intervals change = week 16 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.7" lower_limit="-34.8" upper_limit="-0.7"/>
                    <measurement group_id="O2" value="-53.6" lower_limit="-70.1" upper_limit="-37.1"/>
                    <measurement group_id="O3" value="-43.6" lower_limit="-60.7" upper_limit="-26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Post-prandial Glucose From Week 0(Baseline) to Week 16</title>
        <description>mean change in post-prandial glucose from Week 0(baseline) to week 16 with standard deviation change = week 16 - week 0.</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Post-prandial Glucose From Week 0(Baseline) to Week 16</title>
          <description>mean change in post-prandial glucose from Week 0(baseline) to week 16 with standard deviation change = week 16 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.1" spread="62.73"/>
                    <measurement group_id="O2" value="-54.0" spread="67.51"/>
                    <measurement group_id="O3" value="-40.9" spread="65.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0374</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Post-prandial Insulin From Week 0(Baseline) to Week 16</title>
        <description>mean change in post-prandial insulin from Week 0(baseline) to week 16 with standard deviation change = week 16 - week 0.</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Post-prandial Insulin From Week 0(Baseline) to Week 16</title>
          <description>mean change in post-prandial insulin from Week 0(baseline) to week 16 with standard deviation change = week 16 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.898" spread="22.8717"/>
                    <measurement group_id="O2" value="1.962" spread="26.0326"/>
                    <measurement group_id="O3" value="4.832" spread="24.6608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2701</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6117</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2007</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Low-Density Lipoprotein-C(LDL-C) From Week 0(Baseline) to Week 16 Least Squares Mean</title>
        <description>change in LDL-C from Week 0(baseline) to week 16 least squares mean with 95% confidence intervals change = week 16 - week 0.</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low-Density Lipoprotein-C(LDL-C) From Week 0(Baseline) to Week 16 Least Squares Mean</title>
          <description>change in LDL-C from Week 0(baseline) to week 16 least squares mean with 95% confidence intervals change = week 16 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.5" lower_limit="-26.5" upper_limit="-12.6"/>
                    <measurement group_id="O2" value="4.9" lower_limit="-1.8" upper_limit="11.5"/>
                    <measurement group_id="O3" value="6.2" lower_limit="-0.7" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in LDL-C From Week 0(Baseline) to Week 16</title>
        <description>mean change in LDL-C from Week 0(baseline) to week 16 with standard deviation change = week 16 - week 0.</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in LDL-C From Week 0(Baseline) to Week 16</title>
          <description>mean change in LDL-C from Week 0(baseline) to week 16 with standard deviation change = week 16 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.7" spread="23.85"/>
                    <measurement group_id="O2" value="5.5" spread="28.27"/>
                    <measurement group_id="O3" value="5.7" spread="22.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1864</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0999</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage of Change in LDL-C Levels From Week 0(Baseline) to Week 16</title>
        <description>mean percent change in LDL-C levels from Week 0(baseline) to Week 16 mean with standard deviation change = week 16 - week 0.</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Change in LDL-C Levels From Week 0(Baseline) to Week 16</title>
          <description>mean percent change in LDL-C levels from Week 0(baseline) to Week 16 mean with standard deviation change = week 16 - week 0.</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>% change in LDL-C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.40" spread="19.443"/>
                    <measurement group_id="O2" value="7.41" spread="25.989"/>
                    <measurement group_id="O3" value="7.61" spread="21.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0566</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value presents results from 1-sample t-test for within-treatment difference from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0217</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage of Change in LDL-C Levels From Week 0(Baseline) to Week 16 (Least Squares Mean)</title>
        <description>percent change in LDL-C levels from Week 0(baseline) to Week 16 (least squares mean with 95% confidence interval)</description>
        <time_frame>16 weeks change = week 16 - week 0.</time_frame>
        <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Colesevelam</title>
            <description>colesevelam tablets 625 mg</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>rosiglitazone maleate 4mg</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>sitagliptin phosphate tablets 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Change in LDL-C Levels From Week 0(Baseline) to Week 16 (Least Squares Mean)</title>
          <description>percent change in LDL-C levels from Week 0(baseline) to Week 16 (least squares mean with 95% confidence interval)</description>
          <population>The Full Analysis Set population included all randomized subjects who had taken at least 1 dose of study medication, and had a baseline and at least 1 post baseline HbA1c measurement.</population>
          <units>% change in LDL-C</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.24" lower_limit="-22.68" upper_limit="-9.81"/>
                    <measurement group_id="O2" value="6.92" lower_limit="0.76" upper_limit="13.08"/>
                    <measurement group_id="O3" value="7.98" lower_limit="1.62" upper_limit="14.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reflects the following restrictive language in the Clinical Study Agreements: &quot;If identified by DSI, any of DSI's confidential information as defined herein shall be deletedâ¦Nothing in this publication section shall be taken as giving DSI any right of editorial control over any publication prepared by the Study Site.&quot;</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Raia, Director, Professional Affairs</name_or_title>
      <organization>Daiichi Sankyo Inc.</organization>
      <phone>973-630-2683</phone>
      <email>jraia@dsus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

